

CLAIMS:

1. A nucleic acid encoding the carboxy-terminal portion of the heavy chain (H_C) of botulinum neurotoxin (BoNT) selected from the group consisting of BoNT serotype A, BoNT serotype B, BoNT serotype C_1 , BoNT serotype D, BoNT serotype E, BoNT serotype F, and BoNT serotype G, wherein said nucleic acid is expressable in a recombinant organism selected from *Escherichia coli* and *Pichia pastoris*.
2. The nucleic acid of claim 1, wherein said nucleic acid comprises a nucleic acid sequence selected from SEQ ID No:1 (serotype A), SEQ ID No:7 (serotype B), SEQ ID No:9 (serotype C_1), SEQ ID No:11 (serotype D), SEQ ID No:13 (serotype E), SEQ ID No:15 (serotype F), and SEQ ID No:17 (serotype G).
3. The nucleic acid of claim 1, wherein the nucleic acid encodes an H_C amino acid sequence of BoNT selected from SEQ ID No:2 (serotype A), SEQ ID No:8 (serotype B), SEQ ID No:10 (serotype C_1), SEQ ID No:12 (serotype D), SEQ ID No:14 (serotype E), SEQ ID No:16 (serotype F), and SEQ ID No:18 (serotype G).
4. A nucleic acid encoding the amino-terminal portion of the heavy chain (H_N) of botulinum neurotoxin (BoNT) selected from the group consisting of BoNT serotype B, BoNT serotype C_1 , BoNT serotype D, BoNT serotype E, BoNT serotype F, and BoNT serotype G, wherein said nucleic acid is expressable in a recombinant organism selected from *Escherichia coli* and *Pichia pastoris*.
5. The nucleic acid of claim 4, wherein said nucleic acid comprises a nucleic acid sequence selected from SEQ ID No:21 (serotype B), SEQ ID No:23 (serotype C_1), SEQ ID No:25 (serotype D), SEQ ID No:27 (serotype E), SEQ ID No:29 (serotype F), and SEQ ID No:31 (serotype G).
6. The nucleic acid of claim 4, wherein the nucleic acid encodes an H_N amino acid sequence of BoNT selected from SEQ ID No:22 (serotype B), SEQ ID No:24 (serotype C_1), SEQ ID No:26 (serotype D), SEQ ID No:28 (serotype E), SEQ ID No:30 (serotype F), and SEQ ID No:32 (serotype G).

7. The nucleic acid of any one of claims 1, 3, 4, or 6, wherein the sequence of the nucleic acid is designed by selecting at least a portion of the codons encoding H_C from codons preferred for expression in a host organism.

5

8. The nucleic acid of claim 7, wherein the host organism is selected from gram negative bacteria, yeast, and mammalian cell lines.

9. The nucleic acid of claim 8, wherein the host organism is *Escherichia coli* or
10 *Pichia pastoris*.

10. The nucleic acid of any one of claims 1, 3, 4, or 6, wherein the nucleic acid sequence encoding H_C is designed by selecting codons encoding H_C which codons provide H_C sequence enriched in guanosine and cytosine residues.

15

11. The nucleic acid of any one of claims 1, 3, 4, or 6, wherein said nucleic acid is a synthetic nucleic acid.

12. The nucleic acid of any one of claims 1, 3, 4, or 6, wherein said nucleic acid encoding H_C or H_N is expressed in a recombinant host organism with higher yield than a second nucleic acid fragment encoding the same H_C sequence, said second nucleic acid fragment having the wild-type *Clostridium botulinum* sequence of H_C.
20

13. An expression vector comprising the nucleic acid of any one of claims 1, 3, 25 4, or 6, whereby H_C or H_N is expressed upon transfection of a host organism with said expression vector.

14. A method of preparing a polypeptide comprising the carboxy-terminal portion of the heavy chain (H_C) of botulinum neurotoxin (BoNT) or the amino-terminal portion of the heavy chain (H_N) of botulinum neurotoxin (BoNT) selected from the group consisting of BoNT serotype A, BoNT serotype B, BoNT serotype C, BoNT serotype D, BoNT serotype E, BoNT serotype F, and BoNT serotype G,
30

said method comprising culturing a recombinant host organism transfected with the expression vector of claim 13 under conditions wherein H_C or H_N is expressed.

15 The method of claim 14, wherein the recombinant host organism is a eukaryote.

16. The method of claim 14, further comprising recovering insoluble protein from said host organism, whereby a fraction enriched in H_C or H_N is obtained.

10 17. The method of claim 16, wherein said host organism is *Pichia pastoris*.

15 18. An immunogenic composition comprising the carboxy-terminal portion of the heavy chain (H_C) of botulinum neurotoxin (BoNT) selected from the group consisting of BoNT serotype A, BoNT serotype B, BoNT serotype C, BoNT serotype D, BoNT serotype E, BoNT serotype F, and BoNT serotype G.

19. The immunogenic composition of claim 18, wherein H_C is prepared by culturing a recombinant organism transfected with an expression vector encoding H_C .

20 20. The immunogenic composition of claim 19, wherein an insoluble protein fraction enriched in H_C is recovered from said recombinant organism.

25 21. An immunogenic composition comprising the amino-terminal portion of the heavy chain (H_N) of botulinum neurotoxin (BoNT) selected from the group consisting of BoNT serotype A, BoNT serotype B, BoNT serotype C, BoNT serotype D, BoNT serotype E, BoNT serotype F, and BoNT serotype G.

30 22. The immunogenic composition of claim 21, wherein H_N is prepared by culturing a recombinant organism transfected with an expression vector encoding H_N .

09101951072004

23. The immunogenic composition of claim 22, wherein an insoluble protein fraction enriched in H_N is recovered from said recombinant organism.

24. An immunogenic composition comprising a polypeptide comprising epitopes contained in the carboxy-terminal portion of the heavy chain (H_C) of botulinum neurotoxin (BoNT) or the amino-terminal portion of the heavy chain (H_N) of botulinum neurotoxin (BoNT) selected from the group consisting of BoNT serotype A, BoNT serotype B, BoNT serotype C, BoNT serotype D, BoNT serotype E, BoNT serotype F, and BoNT serotype G, said epitopes eliciting protective immunity toward the respective BoNT serotype.

25. The immunogenic composition of claim 24, wherein said immunogenic composition elicits an ELISA response to the respective BoNT serotype in an animal, said ELISA response being detectable upon 100-fold dilution of serum from said animal.

26. An immunogenic composition comprising a protein containing at least a portion of a botulinum neurotoxin (BoNT) sequence, said BoNT being selected from the group consisting of BoNT serotype A, BoNT serotype B, BoNT serotype C, BoNT serotype D, BoNT serotype E, BoNT serotype F, and BoNT serotype G.

27. The immunogenic composition of claim 26, wherein said portion of BoNT sequence elicits an ELISA response to the respective BoNT serotype in an animal, said ELISA response being detectable upon 100-fold dilution of serum from said animal.

28. The immunogenic composition of claim 26, wherein said protein is a fusion protein further comprising a non-toxic polypeptide sequence.

29. The immunogenic composition of claim 26, wherein said composition is endotoxin free.

30. The immunogenic composition of claim 26, wherein the portion of BoNT sequence is a portion of carboxy-terminal heavy chain (H_C) sequence or amino-terminal heavy chain (H_N) sequence.

5 31. A nucleic acid encoding a protein containing at least a portion of a botulinum neurotoxin (BoNT) sequence, said BoNT being selected from the group consisting of BoNT serotype A, BoNT serotype B, BoNT serotype C, BoNT serotype D, BoNT serotype E, BoNT serotype F, and BoNT serotype G.

10 32. The nucleic acid of claim 31, wherein said protein containing at least a portion of BoNT sequence elicits an ELISA response to the respective BoNT serotype in an animal, said ELISA response being detectable upon 100-fold dilution of serum from said animal.

15 33. An expression vector comprising the nucleic acid of claim 31.

34. A recombinant host cell containing the expression vector of claim 33.

35 The recombinant host cell of claim 34, wherein said host cell expresses a
20 protein containing at least a portion of BoNT sequence, said portion of BoNT sequence containing at least one protective epitope of the respective BoNT serotype.

36. The recombinant host cell of claim 34, wherein said host cell expresses a protein containing at least a portion of BoNT sequence, and wherein said protein
25 elicits an ELISA response to the respective BoNT serotype in an animal, said ELISA response being detectable upon 100-fold dilution of serum from said animal.

37. The recombinant host cell of claim 34, wherein said host cell expresses a protein containing at least a portion of BoNT sequence, said protein making up at
30 least 0.75% of the total cellular protein.

0940196 072004
T00220 98707600

38. The recombinant host cell of claim 34, wherein said host cell expresses a protein containing at least a portion of BoNT sequence, said protein making up at least 20% of the total cellular protein.

1002601307659